Back to top

Press Releases

Zacks Equity Research

Zacks.com featured highlights: Chimera Investment, PennyMac Financial Services and Sucampo Pharmaceuticals

CIM PFSI SCMP

Trades from $3

For Immediate Release

Chicago, IL – November 30, 2016 - Stocks in this week’s article include Chimera Investment Corp. (NYSE:(CIM - Free Report) –Free Report),PennyMac Financial Services (NYSE:(PFSI - Free Report) –Free Report) and Sucampo Pharmaceuticals (NASDAQ:(SCMP - Free Report) – Free Report).

Screen of the Week of Zacks Investment Research by Kevin Matras:

This Value Screen Is Our Top Performer This Year

Value investors and traders favor good stocks at great prices. This does not mean they have to be cheap in price though.

The key is the belief that they are undervalued. That they are, for some reason, trading under what their true value or potential really is. And the value investor hopes to get in before the market 'discovers' this and moves higher.

Value investing became famous from legendary investor Benjamin Graham, and more recently Warren Buffett. Obviously, they know something. And they do.

In fact, value investing has proven to be one of the most successful forms of investing over time.

Let's take a look at our 'Value Method 1' screen (which is our top performing screen so far this year) and how you too can benefit from value investing.

Parameters

Zacks Rank less than or equal to 2
(Only Zacks Rank #1 Strong Buys and #2 Buys will get through. This immediately tilts the odds of success in our favor as they've handily beaten the market by nearly 3 times and 2 times as much, respectively.)

% Change Actual EPS (Q0/Q-1) greater than X Industry Median
(EPS growth above the median for their expanded industry. Too many value stocks are cheap because there's no real growth to speak of. This item selects stocks with growth rates above the median for their industry, and specifically excludes those below it.)

P/E Ratio Using 12 Month EPS less than X Industry Median
(P/E ratio below the median for its industry. Certain items have averages or medians that vary from industry to industry. This identifies only those trading at a discount to the median to their peers.)

Price/Sales Ratio less than X Industry Median
(This is my favorite valuation metric. The P/S ratio is calculated as price divided by sales. If a stock is trading at a P/S ratio of 1, that means you're paying $1 for every $1 of sales the company makes. If a stock has a P/S ratio of 2, that means you're paying $2 for every $1 of sales the company makes. As you can see, the lower the number, the better. If a stock has a P/S ratio of .5, that means you're paying 50 cents for every $1 of sales the company makes. Like the P/E ratio, different industries have different P/S ratios that are considered normal. So we'll be focusing on stocks with a P/S ratio less than the median for its industry.)

(% Rating Change over 1 Week) + (% Change Q1 Estimate over 4 Weeks) + (% Change F1 Estimate over 4 Weeks) = Top # 7
(This calculated expression combines three items together because of their predictive performance. Stocks with positive broker rating changes (broker rating upgrades) outperform those with broker rating downgrades, and those with no broker rating change at all. And stocks with upward earnings estimate revisions tend to receive more upward earnings estimate revisions, which often leads to higher prices. Using the current quarter and the current year shows increased optimism for both the short-term and the longer-term. Only the 7 stocks with the highest scores for all three items combined get picked.)

Results

Over the last 16 years (2000 thru 2015), using a one-week holding period, this strategy has shown an average annual return of 49.8% vs. the S&P's 3.8%.

And so far in 2016 (thru 11/25/16), it's up 156% vs. the market's total return of 10.5%.

It was designed to hold 7 stocks in its portfolio at a time. It's rebalanced weekly. And it trades on average of 4 stocks a week.

One of the potential drawbacks with some value screens is that you often have to wait awhile before the market recognizes that it has mispriced (undervalued) a certain stock and starts to move higher. Some value stocks, for whatever reason, have been ignored by the market. Hence the typically longer-time horizon while you wait for the market to take notice.

But there's no better catalyst to get a stock moving than a series of upward earnings estimate revisions. Throw in a broker rating upgrade, and the timeliness of the Zacks Rank, and you have a list of stocks with virtually every reason to move up - and fast.

Stocks

There are 7 new stocks coming thru this screen this week. Here are 3 of them:

(NYSE:(CIM - Free Report) – Free Report) Chimera Investment Corp.
(NYSE:(PFSI - Free Report) – Free Report) PennyMac Financial Services
(NASDAQ:(SCMP - Free Report) – Free Report) Sucampo Pharmaceuticals

Get the rest of the stocks on this list and start looking for the newest companies that fit these criteria. It's easy to do. And it could help you find your next big winner. Start screening for these companies today with a free trial to the Research Wizard. You can do it.

Click here to sign up for a free trial to the Research Wizard today .

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance .

Zacks Restaurant Recommendations: In addition to dining at these special places, you can feast on their stock shares. A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector. Download it free »

Sign up now for your free trial today and start picking better stocks immediately. And with the backtesting feature, you can test your ideas to see how you can improve your trading in both up markets and down markets. Don’t wait for the market to get better before you decide to do better. Start learning how to be a better trader today: https://at.zacks.com/?id=111

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use. Each week, Zacks Profit from the Pros free email newsletter shares a new screening strategy. Learn more about it here https://at.zacks.com/?id=112

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Click here for your free subscription to Profit from the Pros.

Get the full Report on CIM - FREE

Get the full Report on PFSI - FREE

Get the full Report on SCMP - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com

Visit: https://www.zacks.com/performance

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer .

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

CHIMERA INVEST (CIM) - free report >>

PENNYMAC FIN SV (PFSI) - free report >>

SUCAMPO PHARMAC (SCMP) - free report >>